Stock events for Organogenesis Holdings, Inc. (ORGO)
Organogenesis Holdings, Inc. stock has experienced significant volatility over the past six months. While the company reported strong financial results for Q4 2025, the stock fell due to market concerns over regulatory changes and competitive pressures. The company warned of a potential revenue decline in 2026 due to regulatory disruptions. Analyst ratings have varied, with some upgrading the stock and others decreasing the price target. Insider selling has also been noted.
Demand Seasonality affecting Organogenesis Holdings, Inc.’s stock price
Information regarding specific demand seasonality for Organogenesis Holdings, Inc. products and services was not explicitly found in the provided search results.
Overview of Organogenesis Holdings, Inc.’s business
Organogenesis Holdings, Inc. is a regenerative medicine company that develops, manufactures, and commercializes solutions for advanced wound care and surgical and sports medicine markets. The company offers a diverse portfolio of bioactive and acellular biomaterials products, including advanced wound care products like Apligraf and Dermagraft, and surgical and sports medicine products like NuShield and PuraForce. Organogenesis also has pipeline products such as ReNu, which is in Phase 3 trials for knee osteoarthritis, with a BLA submission expected to be completed in the first half of 2026.
ORGO’s Geographic footprint
Organogenesis Holdings, Inc. is headquartered in Canton, Massachusetts, U.S. The company generates substantially all of its sales within the United States, serving hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.
ORGO Corporate Image Assessment
Organogenesis' brand reputation has been influenced by both positive and challenging events in the past year. Impressive revenue growth and optimistic analyst ratings contribute positively, as does the initiation of the BLA submission for ReNu. However, the projected revenue decline for 2026 due to CMS regulatory changes and investigations by law firms could negatively impact its brand perception and investor confidence.
Ownership
Organogenesis Holdings, Inc. is a publicly traded entity on the Nasdaq Capital Market under the ticker ORGO. Its ownership structure includes a mix of institutional and individual investors. Major institutional holders include Morgan Stanley, Soleus Capital Management, and Vanguard Group Inc. Individual investors include members of the founding Ades family and CEO Gary S. Gillheeney, Sr.
